AlzecaBiosciences 认领应用

Alzeca is developing a proprietary imaging agent, "ADx", to diagnose early stage Alzheimer's Disease. ADx is delivered intravenously and is designed to bind to Alzheimer's disease pathology (beta-amyloid protein) in the brain. ADx is loaded with a contrast agent that highlights beta amyloid when the patient undergoes an imaging scan. ADx enabled diagnosis projects to be lower cost, more effective, and far more accesible in comparison to current and emerging Alzheimer's diagnostic approaches.